Back to Search
Start Over
Evaluation of metabolic response with 18F-FDG PET-CT in patients with advanced or recurrent thymic epithelial tumors
- Source :
- Cancer Imaging, Cancer imaging (Online) 17 (2017). doi:10.1186/s40644-017-0112-x, info:cnr-pdr/source/autori:Segreto, Sabrina; Fonti, Rosa; Ottaviano, Margaret; Pellegrino, Sara; Pace, Leonardo; Damiano, Vincenzo; Palmieri, Giovannella; Del Vecchio, Silvana/titolo:Evaluation of metabolic response with F-18-FDG PET-CT in patients with advanced or recurrent thymic epithelial tumors/doi:10.1186%2Fs40644-017-0112-x/rivista:Cancer imaging (Online)/anno:2017/pagina_da:/pagina_a:/intervallo_pagine:/volume:17
- Publication Year :
- 2017
- Publisher :
- BioMed Central, 2017.
-
Abstract
- BACKGROUND: Patients with advanced or recurrent thymic epithelial tumors (TETs) often need several consecutive lines of chemotherapy. The aim of this retrospective monocentric study was to test whether 18F-Fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET-CT) is able to monitor standard chemotherapy efficacy in those patients and whether metabolic response correlates with morphovolumetric response as assessed by Response Evaluation Criteria in Solid Tumor (RECIST). METHODS: We evaluated 27 consecutive patients with advanced (16 patients) or recurrent (11 patients) TETs. All patients underwent 18F-FDG PET-CT before and after at least 3 cycles of chemotherapy. Maximum standardized uptake value (SUVmax) of all detected lesions was recorded and the most 18F-FDG avid lesion in each patient was selected for determination of percentage change of SUVmax (ΔSUVmax) in pre- and post-treatment scans. Tumor response was assessed by contrast-enhanced computed tomography (CE-CT) using RECIST criteria. Receiver operating characteristic (ROC) curve analysis was performed to define the optimal threshold of ΔSUVmax discriminating responders from non-responders. RESULTS: Metabolic response expressed as ΔSUVmax was significantly correlated with morphovolumetric response (Spearman's rank correlation, r = 0.64, p = 0.001). ROC curve analysis showed that a ΔSUVmax value of -25% could discriminate responders from non-responders with a sensitivity of 88% and a specificity of 80%. Conversely, basal SUVmax values were not predictive of morphovolumetric tumor response. CONCLUSIONS: Our findings indicate that metabolic response assessed by 18F-FDG PET-CT, through evaluation of ΔSUVmax, may allow identification of responders and non-responders thus guiding adaptation of therapy in patients with advanced or recurrent TETs.
- Subjects :
- Male
Thymoma, Thymic carcinoma, 18F-FDG PET-CT, Tumor response, RECIST
medicine.medical_treatment
030218 nuclear medicine & medical imaging
Basal (phylogenetics)
0302 clinical medicine
Positron Emission Tomography Computed Tomography
Medicine
Neoplasms, Glandular and Epithelial
Thymic carcinoma
Aged, 80 and over
Radiological and Ultrasound Technology
18F-FDG PET-CT
General Medicine
Middle Aged
F-18-FDG PET-CT
Treatment Outcome
Oncology
Radiology Nuclear Medicine and imaging
030220 oncology & carcinogenesis
Female
Radiology
medicine.symptom
Research Article
Adult
medicine.medical_specialty
Thymoma
Standardized uptake value
Antineoplastic Agents
Lesion
03 medical and health sciences
Fluorodeoxyglucose F18
Humans
Radiology, Nuclear Medicine and imaging
Aged
Retrospective Studies
Chemotherapy
Receiver operating characteristic
business.industry
Retrospective cohort study
Thymus Neoplasms
medicine.disease
RECIST
ROC Curve
Tumor response
Radiopharmaceuticals
business
Tomography, X-Ray Computed
Subjects
Details
- Language :
- English
- ISSN :
- 14707330 and 17405025
- Volume :
- 17
- Database :
- OpenAIRE
- Journal :
- Cancer Imaging
- Accession number :
- edsair.doi.dedup.....4884bcab93adc1b43cd62a4f5cd7b035